Aspira Women's Health gets $10M ARPA-H award for endometriosis blood test

Aspira Women's Health Inc.

Selected by ARPA-H for $10 million in milestone-based funding over two years to develop EndoMDx blood test for endometriosis.
EndoMDx is a multi-marker miRNA blood test intended to aid in detection, currently requiring laparoscopic surgery for diagnosis.
Over 1,700 submissions vied for funding; Aspira will collaborate with ARPA-H Program Manager and Investor Catalyst Hub.
Virtual Investor Day scheduled for October 29, 2024, at 3:00 pm ET to discuss ARPA-H award and pipeline update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.